Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @jeff_cranmer
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @jeff_cranmer
-
$GSK will provide its AS03 adjuvant technology to enhance#2019nCoV vaccines that are being funded by@CEPIvaccines. Story: https://www.biocentury.com/article/304359#coronavirusHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jeffrey Cranmer proslijedio/la je Tweet
Folks -
@BioCentury is continuing to cover the#Coronavirus outbreak, which is outside the paywall. This contains the therapeutic & preventive developments, policy actions, and biopharma response.https://www.biocentury.com/coronavirusHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Approval of
@aimmune#peanutallergy therapy huge step in right direction for food allergy patients, families, lends important validation to long-held theory that desensitization is effective to treat food allergies, writes@BioCentury's@Laurenmmartz https://www.biocentury.com/article/304347$AIMTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jeffrey Cranmer proslijedio/la je Tweet
Summary of the week. Be prudent. Prepare for the worst and Hope for the best. Follow the data and listen to the science. Do everything we can in the meantime. The cost of under reacting is worse than some worry. This is NOT an existential threat, but there are many unknowns.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
20% of industry-sponsored clinical trials in China have a site in Wuhan, the epicenter of the 2019-nCoV
#coronavirus outbreak. Most of those are late-stage.https://www.biocentury.com/article/304351Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@HHSGov declares #2019-nCoV public health emergency. Another declaration needed for@US_FDA to issue Emergency Use Authorizations for use of unapproved diagnostics, drugs or vaccines@biocentury's@steveusdin1 reports:https://www.biocentury.com/article/304341Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Brexit's complete.@BIA_UK's Steve Bates speaks with@BioCentury's@StephenPHansen about the trade group's priorities in shaping UK life sci sector's new relationship w/EUhttps://www.biocentury.com/article/304340Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A dozen vaccine programs under way as
@WHO declares#coronavirus public health emergency. Details via@BioCentury's@steveusdin1https://www.biocentury.com/bc-extra/clinical-news/2020-01-30/industry-and-academic-centers-are-rushing-create-new-vaccines-and- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jeffrey Cranmer proslijedio/la je Tweet
A dozen #2019-nCoV vaccine development programs have been announced, five efforts to discover and develop therapeutic antibodies.
@V2019N https://www.biocentury.com/bc-extra/clinical-news/2020-01-30/industry-and-academic-centers-are-rushing-create-new-vaccines-and- …pic.twitter.com/GWcSDuBcZg
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A
#Medicaid program rolled out Thursday allows states to create restrictive drug formularies while also receiving rebates from drug manufacturers. It's likely headed for the courts, writes@BioCentury@steveusdin1https://www.biocentury.com/bc-extra/politics-policy/2020-01-30/trump-administration-allows-medicaid-drug-formularies …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Arch co-leads $14M series A for Vizgen, which aims to overcome capacity limitations of single-cell RNA imaging tech. Co-founder David Walt is scientific founder of 2 other Arch portfolio cos:
$ILMN &$QTRX via@LaboratoryLiz in@BioCenturyhttps://www.biocentury.com/biocentury/finance/2020-01-30/arch-thinks-vizgen%E2%80%99s-technology-could-improve-transcriptome-imaging- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jeffrey Cranmer proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Jeffrey Cranmer proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Jeffrey Cranmer proslijedio/la je Tweet
LIVE: Press conference on the Emergency Committee meeting on
#2019nCoVhttps://www.pscp.tv/w/cQMn-DI2MTAyMHwxZWFKYlFiak5RWEdYmpLO90HLNRBTXqtx4Q-cqWn1WcPGkx9aaO-PK6Jsavs= …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
W/ $45M series B led by Decheng,
@mammothbiosci looks to capitalize on IP position around alternative#CRISPR enzyme, expand gene editing capabilities beyond Dx to therapeutic applications.@biocentury's@Laurenmmartz talks w/ CEO Trevor Martin:https://www.biocentury.com/bc-extra/preclinical-news/2020-01-30/crispr-company-mammoth-looks-beyond-diagnostics-decheng- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jeffrey Cranmer proslijedio/la je Tweet
Center for Communicable Disease Dynamics offers ‘tweetorial’ on coronavirushttps://www.hsph.harvard.edu/news/features/coronavirus-wuhan-china-lipsitch/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Black Diamond raises $200M in
#IPO. The precision oncology company had raised $194M in venture $ since 2014 launch from VCs including Versant (31% stake), NEA (8%), RA (5%)$BDTXhttp://www.globenewswire.com/news-release/2020/01/30/1977162/0/en/Black-Diamond-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jeffrey Cranmer proslijedio/la je Tweet
CVS eliminating co-pays for insulin and diabetes meds. A step in the right direction say biopharma leaders who want to uphold the social contract. Via
@Laurenmmartz in@BioCenturyhttps://www.biocentury.com/bc-extra/politics-policy/2020-01-29/industry-leaders-applaud-cvs-zero-co-pay-diabetes-drug-access …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
1/2 Under the leadership of incoming CEO Laurence Reid,
#HearingLoss co@DecibelTx begins new chapter in drug discovery w/narrowed focus on inner ear cell regeneration and programs in balance disorders. via@BioCenturyhttps://www.biocentury.com/bc-extra/company-news/2020-01-29/decibel-narrows-discovery-focus-inner-ear-regeneration-taps-reid- …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
BREAKING
’s commitment to transparency and to supporting other countries"-